SUPN FY 2016 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

FY 2016 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$215M+48.9% YoY

Gross Profit

$203M94.4% margin

Operating Income

$54M25.2% margin

Net Income

$91M42.4% margin

EPS (Diluted)

$1.76

Cash Flow

Operating Cash Flow

$67M

Free Cash Flow

$65M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$310M

Total Liabilities

$118M

Stockholders' Equity

$192M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$215M	$144M	+48.9%
Gross Profit	$203M	$136M	+49.3%
Operating Income	$54M	$18M	+206.9%
Net Income	$91M	$14M	+550.8%